EVIDENCE FOR A 1,2-HYDRIDE SHIFT IN THE MICROSOMAL METABOLISM OF THE HETEROCYCLE L-158,338, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST

被引:0
|
作者
STEARNS, RA
MILLER, RR
ARISON, BH
ROSEGAY, A
SMITH, JL
MANTLO, NB
CHIU, SHL
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
L-158,338 is an imidazo[4,5-b]pyridine derivative that is a potent and highly selective angiotensin II receptor antagonist. Rat liver microsomal metabolism of [C6-H-3]L-158,338 gave a major metabolite that was monohydroxylated at the C6 position of the imidazo-pyridine but showed partial retention of the radiolabel. This biotransformation necessitated a shift of the radiolabel from the C6 position to another site within the molecule. We have investigated the mechanism of this biotransformation using H-3-, H-3/C-14-, and H-2-labeled L-158,338. Metabolites were identified by FAB/MS, LC/MS, and H-1-NMR. Results of these studies show that the microsomal metabolism of L-158,338 to its C6-monohydroxylated derivative was mediated by a 1,2 hydride shift.
引用
收藏
页码:670 / 676
页数:7
相关论文
共 39 条
  • [1] INVIVO PHARMACOLOGY OF A HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II (AII) RECEPTOR ANTAGONIST - L-158,809
    SIEGL, PKS
    CHANG, RS
    GREENLEE, WJ
    LOTTI, VJ
    MANTLO, NB
    PATCHETT, AA
    SWEET, CS
    FASEB JOURNAL, 1991, 5 (06): : A1576 - A1576
  • [2] INVITRO PHARMACOLOGY OF A HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II (AII) RECEPTOR ANTAGONIST - L-158,809
    CHANG, RSL
    SIEGL, PKS
    CLINESCHMIDT, BV
    MANTLO, NB
    CHAKRAVARTY, PK
    GREENLEE, WJ
    PATCHETT, AA
    LOTTI, VJ
    FASEB JOURNAL, 1991, 5 (06): : A1575 - A1575
  • [3] INVIVO PHARMACOLOGY OF L-158,809, A NEW HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    SIEGL, PKS
    CHANG, RSL
    MANTLO, NB
    CHAKRAVARTY, PK
    ONDEYKA, DL
    GREENLEE, WJ
    PATCHETT, AA
    SWEET, CS
    LOTTI, VJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 262 (01): : 139 - 144
  • [4] OCULAR PENETRATION AND INTRAOCULAR-PRESSURE (IOP) LOWERING ACTIVITY OF THE ANGIOTENSIN-II (AII) ANTAGONISTS LOSARTAN AND L-158,338
    MALLORGA, P
    SUGRUE, MF
    VISION RESEARCH, 1995, 35 : P324 - P324
  • [5] PHARMACOLOGICAL CHARACTERIZATION OF L-158,809, A NONPEPTIDE ANGIOTENSIN-AT(1) RECEPTOR ANTAGONIST
    JAISWAL, N
    KHOSLA, MC
    FASEB JOURNAL, 1993, 7 (07): : A1149 - A1149
  • [6] CHARACTERIZATION OF THE BINDING OF [H-3] L-158,809 - A NEW POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR (AT(1)) ANTAGONIST RADIOLIGAND
    CHEN, TB
    LOTTI, VJ
    CHANG, RSL
    MOLECULAR PHARMACOLOGY, 1992, 42 (06) : 1077 - 1082
  • [7] THE PHARMACOKINETICS AND METABOLISM OF DUP 532, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, IN RATS AND DOGS
    WONG, YN
    HOLM, KA
    BURCHAM, DL
    HUANG, SM
    QUON, CY
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (01) : 53 - 63
  • [8] ANTIHYPERTENSIVE EFFICACY AND EFFECTS ON RENAL-FUNCTION OF L-158,809 - A NONPEPTIDE ORALLY ACTIVE ANGIOTENSIN-II ANTAGONIST
    KIVLIGHN, SD
    GABEL, RA
    SIEGL, PKS
    HYPERTENSION, 1992, 19 (01) : I135 - I135
  • [9] DISPOSITION OF THE ANGIOTENSIN-II RECEPTOR ANTAGONIST L-158,809 IN RATS AND RHESUS-MONKEYS
    COLLETTI, AE
    KRIETER, PA
    DRUG METABOLISM AND DISPOSITION, 1994, 22 (02) : 183 - 188